Tag: necrotizing enterocolitis market overview

Uncover key drivers, emerging technologies, and competitive movements shaping the necrotizing enterocolitis market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Necrotizing Enterocolitis Market between 2026 and 2030?

The necrotizing enterocolitis market has seen substantial growth in recent years. It is projected to expand from $5.14 billion in 2025 to $5.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been driven by factors such as a high incidence of premature births, limited neonatal care infrastructure, reliance on broad-spectrum antibiotics, delayed diagnosis in low-resource settings, and the early development of parenteral nutrition.

The necrotizing enterocolitis market is anticipated to exhibit robust expansion over the next few years, with its size projected to reach $6.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period can be ascribed to increased investment in neonatal intensive care units, progress in regenerative and stem cell therapies, heightened awareness of early NEC detection, the rising adoption of precision nutrition therapies, and the broadening scope of neonatal imaging innovations. Significant trends expected during this period include the growing acceptance of probiotics and prebiotics for NEC prevention, a greater emphasis on early diagnosis and screening in premature infants, expanding utilization of individualized TPN solutions, the proliferation of minimally invasive surgical interventions, and continuous advancements in neonatal critical care and monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Which Drivers Are Expected To Impact The Necrotizing Enterocolitis Market During The Forecast Period?

A projected increase in premature birth incidents is set to advance the necrotizing enterocolitis market. Premature births, also known as preterm births, signify the delivery of a baby before 37 weeks of gestation, in contrast to the typical 40-week pregnancy term. The rising prevalence of premature births is linked to maternal health conditions such as high blood pressure, diabetes, and infections, which heighten the risk of preterm labor. Additionally, lifestyle factors including smoking, drug use, and insufficient nutrition contribute to a greater likelihood of premature deliveries. A surge in premature births results in more cases of necrotizing enterocolitis (NEC) because premature infants have undeveloped gastrointestinal systems, increasing their susceptibility to inflammation and infection. For instance, in January 2024, as per the Centers for Disease Control and Prevention, a US-based government agency, premature births represent 8.67% of total births in the United States each year. Thus, the growing number of premature births is a key factor propelling the expansion of the necrotizing enterocolitis market.

Which Segments Are Driving Activity In The Necrotizing Enterocolitis Market?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions For TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy For Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

What Industry Trends Are Transforming The Necrotizing Enterocolitis Market?

Leading companies within the necrotizing enterocolitis market are dedicated to developing novel product solutions, including cell-free sterile biologic solutions, to fulfill the pressing need for effective treatments and enhance outcomes for premature infants. Such a solution is a purified, sterile liquid comprising bioactive molecules like proteins, growth factors, and cytokines, derived from cultured cells but entirely free of intact cells, engineered to facilitate healing and diminish inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical firm, obtained clearance from the U.S. Food and Drug Administration (FDA) to commence its Phase 1-2 clinical trial for ST266, an innovative biologic intended for the treatment of necrotizing enterocolitis (NEC) in premature infants. This represents a significant achievement, as ST266 is poised to be the initial major therapeutic advancement for NEC in over 30 years, thereby addressing a crucial medical demand given the high morbidity and mortality rates of the disease among vulnerable populations.

Which Major Firms Are Strengthening Their Position In The Necrotizing Enterocolitis Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Necrotizing Enterocolitis Market?

North America was the largest region in the necrotizing enterocolitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Necrotizing Enterocolitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2026, By The Business Research Company

Viral Gastroenteritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-gastroenteritis-global-market-report

Gastrointestinal Pathogen Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-pathogen-testing-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Necrotizing Enterocolitis Market Valuation Change Between Now And 2029?

The market for necrotizing enterocolitis has seen significant expansion in recent times. The market value is projected to rise from $4.83 billion in 2024 to $5.14 billion in 2025, leveraging a compound annual growth rate (CAGR) of 6.5%. The past growth is due to factors such as the increasing incidence of necrotizing enterocolitis, growing populations, rising per capita income, greater government funding, and a surge in premature birth cases.

In the coming years, the market size for necrotizing enterocolitis is projected to experience robust growth. It is forecasted to grow to $6.56 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.3%. This projected growth during the forecast period can be linked to factors such as escalating healthcare costs, the occurrence and prevalence of ulcerative colitis (UC), the surge in gastrointestinal diseases, the rising number of elderly and overweight individuals, and the burgeoning geriatric population. Some notable trends anticipated during the forecast period include advancements in biomarker research for early NEC detection, progress in non-invasive testing techniques, the adoption of cutting-edge monitoring systems, enhancements in surgical procedures, and the development of targeted treatment modalities.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What Underlying Factors Are Supporting The Necrotizing Enterocolitis Market Growth?

The surge in the number of premature births is anticipated to drive the growth of the necrotizing enterocolitis market in the future. Preterm births, also known as premature births, are when a baby is delivered prior to 37 weeks of pregnancy, as opposed to the standard full-term pregnancy of 40 weeks. The escalation in the incidence of premature births can be traced back to maternal health disorders such as hypertension, diabetes, and infections, which enhance the possibility of premature labor. Moreover, lifestyle factors like smoking, drug consumption, and inadequate nutrition also heighten the chances of preterm births. The rise in premature births subsequently ups the numbers of necrotizing enterocolitis (NEC) cases since newborns with underdeveloped gastrointestinal systems are more vulnerable to inflammation and infections. For example, according to the Centers for Disease Control and Prevention, a government agency in the US, premature births make up 8.67% of all births every year in the United States, as of January 2024. As such, the rise in premature births is accelerating the expansion of the necrotizing enterocolitis market.

Which Sub-Segments Are Driving Growth Within The Necrotizing Enterocolitis Market?

The necrotizing enterocolitismarket covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments

2) By Diagnosis: Laboratory Tests; Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care

What Key Trends Are Driving Growth In The Necrotizing Enterocolitis Market?

Key companies in the necrotizing enterocolitis market are concentrating on developing innovative product solutions like cell-free sterile biologic solutions to meet the urgent need for effective therapies and improve outcomes in premature infants. A cell-free sterile biologic solution is a purified, sterile liquid that contains bioactive molecules—such as proteins, growth factors, and cytokines—sourced from cultured cells but without any living cells, aimed at promoting healing and reducing inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., a US biopharmaceutical firm, received clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 1-2 clinical trial for ST266, an innovative biologic designed to treat necrotizing enterocolitis (NEC) in premature infants. This represents a crucial breakthrough, as ST266 is expected to be the first significant therapeutic advancement for NEC in more than three decades, addressing a pressing medical need given the high rates of morbidity and mortality in this vulnerable patient group.

Which Companies Hold A Competitive Edge In The 1571 Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Region Dominates The Necrotizing Enterocolitis Market Today?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2025, By The Business Research Company

Gastrointestinal Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Gastrointestinal Endoscopy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Necrotizing Enterocolitis Market Expected To Become By 2029 Compared With Its 2025 Level?

The necrotizing enterocolitis market size has demonstrated strong growth in recent years. It is expected to expand from $4.83 billion in 2024 to $5.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed in the past can be ascribed to the increasing prevalence of necrotizing enterocolitis, a rise in global populations, growing per capita income, increased government funding, and a higher number of premature births.

The necrotizing enterocolitis market is projected to experience substantial expansion over the coming years, anticipated to reach a valuation of $6.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period can be attributed to the escalating costs associated with healthcare, the incidence and prevalence of ulcerative colitis (UC), an increase in gastrointestinal diseases, a growing number of geriatric and obese individuals, and the expanding geriatric population overall. Key trends shaping the market over the forecast period include advancements in biomarker research for early NEC detection, developments in non-invasive testing methods, the adoption of advanced monitoring systems, improvements in surgical techniques, and the development of targeted therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What Are The Drivers Pushing New Developments In The Necrotizing Enterocolitis Market?

A rise in premature birth instances is anticipated to drive the expansion of the necrotizing enterocolitis market in the future. Premature births, also known as preterm births, refer to the delivery of a baby before 37 weeks of gestation, in contrast to the typical 40-week pregnancy term. The growing number of premature births stems from maternal health conditions such as high blood pressure, diabetes, and infections, which heighten the risk of preterm labor, and lifestyle factors, including smoking, drug use, and poor nutrition, contribute to a greater probability of these births. An increase in premature births results in a higher incidence of necrotizing enterocolitis (NEC) because premature infants possess underdeveloped gastrointestinal systems, making them more vulnerable to inflammation and infection. For example, data from January 2024, provided by the US government agency Centers for Disease Control and Prevention, indicates that premature births constitute 8.67% of all annual births in the United States. Consequently, the escalating occurrences of premature births are fueling the growth of the necrotizing enterocolitis market.

What Are The Segment Types Shaping The Necrotizing Enterocolitis Market?

The necrotizing enterocolitismarket covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments

2) By Diagnosis: Laboratory Tests; Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care

What Long-Term Trends Will Shape The Future Growth Of The Necrotizing Enterocolitis Industry?

Leading companies in the necrotizing enterocolitis market are concentrating on developing advanced product solutions, such as cell-free sterile biologic solutions, to fulfill the urgent demand for effective treatments and improve outcomes for premature infants. A cell-free sterile biologic solution is defined as a purified, sterile liquid that contains bioactive molecules, including proteins, growth factors, and cytokines, derived from cultured cells but without any intact cells, specifically designed to promote healing and reduce inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical company, received authorization from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 1-2 clinical trial for ST266, a new biologic intended for treating necrotizing enterocolitis (NEC) in premature infants. This signifies an important landmark, as ST266 is projected to be the first significant therapeutic breakthrough for NEC in over 30 years, addressing a critical medical necessity given the disease’s high morbidity and mortality rates among susceptible populations.

Who Are The Top Performing Companies In The Necrotizing Enterocolitis Market In Recent Years?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Necrotizing Enterocolitis Market?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Necrotizing Enterocolitis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2025, By The Business Research Company

Gastrointestinal Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Gastrointestinal Endoscopy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-endoscopy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Necrotizing Enterocolitis Market Size Shifted, And What Is the Outlook Through 2034?

Robust growth has been witnessed in the necrotizing enterocolitis market in the past few years. Its size is projected to escalate from $4.83 billion in 2024 to approximately $5.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.5%. This expansion in the previous period is linked to factors such as an upsurge in the number of necrotizing enterocolitis cases, population growth, enhanced per capita income, increased allocations of government funding, as well as a surge in instances of premature births.

The market for necrotizing enterocolitis is predicted to experience substantial growth in the upcoming years, escalating to a value of$6.56 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this projected growth during the forecast period include the increasing healthcare costs, the rate of occurrence and prevalence of ulcerative colitis (UC), a surge in gastrointestinal diseases, a rise in the population of the elderly and those fighting obesity, and a growing population of the elderly. Key trends forecasted to shape the market include progress in biomarker research to detect NEC early, advances in non-invasive testing methods, the adoption of state-of-the-art monitoring systems, breakthroughs in surgical techniques, and the progression of targeted therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What are the Fundamental Drivers and Innovations Shaping the Necrotizing Enterocolitis Market?

The surge in premature birth instances is anticipated to drive the necrotizing enterocolitis market’s expansion. Preterm births, another term for premature births, occur when a baby is delivered before 37 weeks of gestation, compared to the conventional 40-week pregnancy duration. The rise in premature births can be attributed to various maternal health issues such as hypertension, diabetes, infections, and lifestyle choices such as smoking, drug abuse, and inadequate nutrition. These factors heighten the risk of preterm labor, leading to an increased incidence of premature births. Subsequently, more premature births result in an increased occurrence of necrotizing enterocolitis (NEC), as preterm babies’ gastrointestinal systems are underdeveloped and more prone to inflammation and infection. For example, in January 2024, the Centers for Disease Control and Prevention, a government agency based in the US, reported that premature births make up 8.67% of total annual births in the country. As such, the escalating cases of premature births are propelling the growth of the necrotizing enterocolitis market.

How Is the Necrotizing Enterocolitis Market Segmented?

The necrotizing enterocolitismarket covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments

2) By Diagnosis: Laboratory Tests; Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Which Regions Are Driving the Next Phase of the Necrotizing Enterocolitis Market Growth?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Necrotizing Enterocolitis Market?

Primary businesses in the necrotizing enterocolitis market are concentrating their efforts on creating innovative treatment options, like cell-free sterile biologic remedies, to fill the substantial gap in sufficient treatments and enhance results for premature babies. Cell-free sterile biologic solutions are clean, refined liquids filled with bioactive molecules like proteins, growth stimulants, and cytokines, which originate from cultured cells, but do not contain any intact cells, their objective is to facilitate healing and lower inflammation. In December 2023, for example, the U.S.-based biopharmaceutical firm, Noveome Biotherapeutics, Inc., was greenlit by the U.S. Food and Drug Administration (FDA) to proceed with Phase 1-2 clinical trials for ST266, an innovative biologic designed for necrotizing enterocolitis (NEC) treatment in premature infants. The approval of ST266 is a significant juncture as it is likely to represent the foremost major therapeutic progress for NEC in over 30 years. This addresses a severe health necessity considering the disease’s elevated rates of sickness and death among susceptible groups.

View the full report here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

How Is the Necrotizing Enterocolitis Market Defined and What Are Its Core Parameters?

Necrotizing enterocolitis (NEC) is a serious, potentially life-threatening gastrointestinal condition that primarily affects premature infants. It involves the inflammation and death (necrosis) of the tissue in the intestines, which can lead to perforation, infection, and other complications. The common symptoms of necrotizing enterocolitis include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Necrotizing Enterocolitis Market Grown from 2024 to 2025?

In recent times, there has been a significant expansion in the necrotizing enterocolitis market. The market’s size, which is poised to surge from $4.83 billion in 2024 to $5.16 billion in 2025, will do so at a compound annual growth rate (CAGR) of 6.8%. Factors contributing to the growth throughout the historic period include a rising incidence of necrotizing enterocolitis, population growth, an increase in per capita income, heightened government funding, and a surge in premature birth rates.

What Growth Rate Is Anticipated for the Necrotizing Enterocolitis Market in the Coming Years?

Anticipations are high for substantial growth in the necrotizing enterocolitis market in the coming years, with its size projected to reach $6.62 billion by 2029. This increase, expected at a compound annual growth rate (CAGR) of 6.4%, is due to various factors including rising healthcare costs, occurrence and incidence rates of ulcerative colitis (UC), and elevated gastrointestinal disorders. The surge in elderly and obese population also contributes to this growth, coupled with the upswing in the geriatric population. Key trends expected within this forecast period include progress in biomarker studies for early detection of NEC, breakthroughs in non-invasive diagnostic methods, the utilization of cutting-edge monitoring systems, updates in surgical methodologies, and the evolution of aimed therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Who Are the Leading Companies in the Necrotizing Enterocolitis Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

What Are the Key Drivers of the Necrotizing Enterocolitis Market?

The surge in premature births is anticipated to boost the progress of the necrotizing enterocolitis market in the future. Premature births, often termed preterm births, pertain to delivering a baby prior to the completion of a standard 40-week gestation period, specifically before the 37th week. Factors contributing to this surge include maternal health complications such as high blood pressure, diabetes, infections that escalate the potential for preterm labor, along with lifestyle influences like smoking, substance abuse, and inadequate nutrition, which elevate the odds of premature births. The escalation in preterm births leads to an increased number of necrotizing enterocolitis (NEC) cases because premature babies possess underdeveloped gastrointestinal systems, which enhances their vulnerability to inflammation and infection. For example, per data released by the Centers for Disease Control and Prevention, a government agency in the US, in January 2024, 8.67% of total annual births in the United States are premature. Consequently, the escalating number of premature births is fueling the advancement of the necrotizing enterocolitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

What Are the Key Market Segments in the Necrotizing Enterocolitis Industry?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

What Are the Latest Trends in the Necrotizing Enterocolitis Market?

Leading corporations in the necrotizing enterocolitis market are emphasizing the creation of inventive product solutions, including cell-free sterile biologic solutions, to meet the crucial need for capable treatments and enhance outcomes for premature infants. A cell-free sterile biologic solution constitutes a sterilized, purified fluid housing bioactive elements such as proteins, growth hormones, and cytokines extracted from cultured cells, but void of any intact cells. This solution is structured to stimulate healing and mitigate inflammation. For example, Noveome Biotherapeutics, Inc., an American biopharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) in December 2023 to commence its Phase 1-2 clinical trial for ST266, an innovative biologic product focused on treating necrotizing enterocolitis (NEC) in newborns. This represents a significant leap as ST266 is projected to be the pioneer significant therapeutic progression for NEC in more than 30 years, addressing a fundamental medical requirement considering the disease’s high rates of illness and death among at-risk groups.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

What Are the Key Regional Markets in the Necrotizing Enterocolitis Industry?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

This Report Delivers Insight On:

1. How big is the necrotizing enterocolitis market, and how is it changing globally?

2. Who are the major companies in the necrotizing enterocolitis market, and how are they performing?

3. What are the key opportunities and risks in the necrotizing enterocolitis market right now?

4. Which products or customer segments are growing the most in the necrotizing enterocolitis market?

5. What factors are helping or slowing down the growth of the necrotizing enterocolitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the necrotizing enterocolitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Necrotizing Enterocolitis Market Size Shifted, And What Is the Outlook Through 2034?

The marketplace for necrotizing enterocolitis has seen robust growth in the past years. The market which stands at $4.83 billion in 2024 is projected to rise to $5.16 billion in 2025, recording a compound annual growth rate (CAGR) of 6.8%. Factors such as a surge in the incidences of necrotizing enterocolitis, population growth, an upturn in per capita income, more government funding, and a rise in premature births have fuelled growth during the historical period.

In the coming years, the market for necrotizing enterocolitis is predicted to witness solid expansion, set to reach a valuation of $6.62 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. Several factors contribute to this anticipated growth, including escalating healthcare costs, the prevalence and occurrence of ulcerative colitis (UC), a surge in gastrointestinal diseases, an increase in the elderly and obese populations, and a swelling geriatric populace. The forecast period is expected to see significant trends such as breakthroughs in biomarker studies for early detection of NEC, advancements in non-invasive test procedures, incorporation of sophisticated monitoring systems, improvements in surgical methods, and the creation of specialized therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What Are the Core Growth Drivers Propelling the Necrotizing Enterocolitis Market Forward?

The necrotizing enterocolitis market is expected to experience significant growth due to the rising instances of premature births. Preterm births—defined as the birth of a baby prior to the 37th week of pregnancy as opposed to the standard 40-week term—are becoming increasingly common. The escalation in premature births can be attributed to maternal health issues such as hypertension, diabetes, and infections, which heighten the risk of premature labor. Moreover, lifestyle choices such as smoking, substance misuse, and inadequate nourishment also increase the likelihood of preterm births. As premature babies often possess underdeveloped gastrointestinal systems, they are more vulnerable to inflammation and infection, thereby increasing the incidence of necrotizing enterocolitis (NEC). For example, Centers for Disease Control and Prevention, a government agency based in the US, reported that premature births constituted 8.67% of all US births annually in January 2024. Consequently, the rising prevalence of premature births is fueling the expansion of the necrotizing enterocolitis market.

What Segment Types Define the Necrotizing Enterocolitis Market Structure?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Necrotizing Enterocolitis Market?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theNecrotizing Enterocolitis Industry Evolution?

Several leading corporations in the necrotizing enterocolitis market have shifted their focus to the creation of innovative product solutions, such as cell-free sterile biologic solutions. This new inclination is meant to satisfy the pressing unfulfilled need for efficacious treatments and elevate outcomes for premature babies. A cell-free sterile biologic solution is a purified, aseptic liquid composed of bioactive molecules like proteins, growth factors, and cytokines culled from cultured cells but devoid of any intact cells; it’s purposed for fostering healing and reducing inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc. – a U.S.-based biopharmaceutical enterprise – secured approval from the U.S. Food and Drug Administration to initiate its Phase 1-2 clinical trial for ST266, an innovative biologic geared towards treating necrotizing enterocolitis in premature infants. This development signifies a crucial landmark, as ST266 is expected to be the premier considerable therapeutic progress in the NEC field in over three decades. This aims to address a major healthcare requirement considering the disease’s elevated morbidity and lethality rates among high-risk groups.

View the full report here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

What Is the Definition of the Necrotizing Enterocolitis Market?

Necrotizing enterocolitis (NEC) is a serious, potentially life-threatening gastrointestinal condition that primarily affects premature infants. It involves the inflammation and death (necrosis) of the tissue in the intestines, which can lead to perforation, infection, and other complications. The common symptoms of necrotizing enterocolitis include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model